𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Strategy for lamivudine-resistant YMDD mutant-associated chronic hepatitis B

✍ Scribed by Kendo Kiyosawa; Eiji Tanaka

Book ID
106182426
Publisher
Springer Japan
Year
2001
Tongue
English
Weight
53 KB
Volume
36
Category
Article
ISSN
0944-1174

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Liver transplantation for chronic hepati
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine
✍ Chung Mau Lo; Chi Leung Liu; George K. Lau; See Ching Chan; Irene O. Ng; Sheung πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 95 KB

Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation. Emergence of lamivudine-resistant YMDD mutant is common. We report the results of liver transplantation in 16 patients with pretrans

YMDD mutants in patients with chronic he
YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine
✍ Marie Matsuda; Fumitaka Suzuki; Yoshiyuki Suzuki; Akihito Tsubota; Norio Akuta; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 130 KB

## Abstract Hepatitis B virus (HBV) mutants with mutations in the YMDD motif of viral DNA polymerase/reverse transcriptase are described in patients infected with HBV who have not received lamivudine therapy, but their pathogenetic potential is not clear. These mutants were detected by the polymera

Pre-existing YMDD mutants in treatment-n
Pre-existing YMDD mutants in treatment-naΓ―ve patients with chronic hepatitis B are not selected during lamivudine therapy
✍ Sae Hwan Lee; Hong Soo Kim; In-Seon Byun; Soung Won Jeong; Sang Gyune Kim; Jae Y πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 105 KB

## Abstract Although the rate at which mutations in the tyrosine‐methionine‐aspartate‐aspartate (YMDD) motif of hepatitis B virus polymerase form is high during prolonged lamivudine (LAM) therapy, these mutations sometimes occur naturally in treatment‐naΓ―ve patients with chronic hepatitis B. The pr